Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00094887 · ClinicalTrials.gov registry record · Phase 2
Nitric Oxide Inhalation to Treat Sickle Cell Pain Crises
A Phase 2 study of Anemia, Sickle Cell, sponsored by Mallinckrodt.
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 11
- Study locations
NCT00094887 is a Phase 2 study of Anemia, Sickle Cell that has completed, run by Mallinckrodt. The registered enrollment target is 150 participants, above the 109-participant average among 17 other Anemia, Sickle Cell trials with a reported enrollment target (38% higher). The trial reports 11 study locations across 8 states.
The verdict
NCT00094887, a Phase 2 study of Anemia, Sickle Cell, has completed, sponsored by Mallinckrodt.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 11
- Study locations
Study Summary
This study will examine whether nitric oxide (NO) gas can reduce the time it takes for pain to go away in patients who are in sickle cell crisis. NO is important in regulating blood vessel dilation, and consequently, blood flow. The gas is continuously produced by cells that line the blood vessels. It is also transported from the lungs by hemoglobin in red blood cells. Patients 10 years of age or older with sickle cell disease (known SS, S-beta-thalassemia or other blood problems causing sickle cell disease) may be eligible for this study. Patients whose disease is due to hemoglobin (Hgb) SC are excluded. Candidates are screened with blood tests and a chest x-ray to look at the lungs and heart. Participants are admitted to the hospital in a pain crisis. They are evaluated and then randomly assigned to receive one of two treatments: 1) standard treatment plus NO, or 2) standard treatment plus placebo. The placebo used in this study is nitrogen, a gas that makes up most of the air we breathe and is not known to help in sickle cell disease. For the first 8 hours of the study, patients receive placebo or NO through a facemask. The mask may be taken off for 5 minutes every hour and for not more than 20 minutes to eat a meal. After the first 8 hours, the gas is delivered through a nasal cannula (small plastic tubing that rests under the nose) that may be taken off only while showering or using the restroom. Patients are questioned about the severity of their pain when they start the study and then every few hours while they are in the hospital. Their vital signs (temperature, breathing rate, and blood pressure) and medicines are checked. Patients will breathe the gas for a maximum of 3 days, but will stay hospitalized until the patient feels well enough to go home. Patients are followed up about 1 month after starting the study by a return visit to the hospital or by a phone call.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Nitric Oxide
Study Locations (11)
Maryland
- Johns Hopkins University - Baltimore
- National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda
Massachusetts
- Brigham and Women's Hospital - Boston
- Childrens Hospital, Boston - Boston
Pennsylvania
- St. Christopher's Hospital for Children - Philadelphia
- Childrens Hospital, Pittsburgh - Pittsburgh
Alabama
- University of Alabama - Birmingham
California
- Children's Hospital Oakland - Oakland
Colorado
- Colorado Sickle Cell Treatement and Research Center - Aurora
District of Columbia
- Howard University Hospital - Washington D.C.
Ohio
- Case Western Reserve University Hospital - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2004-10 |
| Est. Completion | 2008-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00094887
The ClinicalTrials.gov registry entry for NCT00094887 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 109-participant average among 17 other Anemia, Sickle Cell trials with a reported enrollment target (38% higher). The listed sponsor is Mallinckrodt, which has 69 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Anemia, Sickle Cell appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00094887 reports 11 study locations spanning 8 distinct geographic areas - top geographies include Maryland, Massachusetts, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00094887 about?
NCT00094887 is a clinical study titled "Nitric Oxide Inhalation to Treat Sickle Cell Pain Crises". This study will examine whether nitric oxide (NO) gas can reduce the time it takes for pain to go away in patients who are in sickle cell crisis. NO is important in regulating blood vessel dilation, and consequently, blood flow. The gas is continuously produced by cells that line the blood vessels. ...
What is the current status of trial NCT00094887?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2004-10. Estimated completion is 2008-12.
What conditions does trial NCT00094887 study?
This clinical trial studies the following conditions: Anemia, Sickle Cell.
What interventions are being tested in trial NCT00094887?
The interventions under investigation include: Placebo (DRUG), Nitric Oxide (DRUG).
Who is sponsoring clinical trial NCT00094887?
This trial is sponsored by Mallinckrodt, which has 69 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00094887 being conducted?
This trial has 11 study locations across Alabama, California, Colorado, District of Columbia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anemia, Sickle Cell
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Socio-ecological Approach for Improving Self-management in Adolescents With SCD
RECRUITING · Phase 2
-
Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia
COMPLETED · Phase 2
-
A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
RECRUITING · Phase 1
-
Metabolic and Hemodynamic Reserve in Pediatric SCA
RECRUITING · NA
-
A Blood Stem Cell Transplant for Sickle Cell Disease
ACTIVE NOT RECRUITING · Phase 1
-
Therapeutic Response Evaluation and Adherence Trial (TREAT)
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.